The “Corporación Catalana de Medios Audiovisuales” has published a report on the RiPCoN project, in which IRB Barcelona’s Structural Bioinformatics and Network Biology is participating.
Cells are more resilient to environmental changes than previously thought
IRB Barcelona launches a scientific collaboration with Galapagos to identify and validate senolytic drug targets in inflammation and fibrosis
Scientists at IRB Barcelona discover the cause of neurodegeneration in Lafora disease
“The Garden of Earthly Delights” by Anna Rierola
Several media channels have reported on the fundraising campaign launched by IRB Barcelona to fund its four research projects on COVID-19.
Link to: eldiario.es
Several media have reported on the platform set up by IRB Barcelona, the Center for Genomic Regulation (CRG) and the Institute for Bioengineering of Catalonia (IBEC) for mass testing for COVID-19, which seeks to contribute to halting the spread of the virus.
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
Alumni - Research Associate
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
Felice Alessio Bava
IRB Barcelona Alumni member
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»